Background
Thromboprophylaxis is a key aspect of care in patients with COVID-19. Description of bleeding events in patients with COVID infection may help to estimate overall risk.
Methods
We reviewed charts for 1000 randomly selected patients from a 10,000 patient database of COVID-19 diagnoses within the University of Colorado health system as of October 2020. We collected demographics, comorbidities, admission status, and ischemic and bleeding outcomes. Bleeding defined as major (critical site or fatal) and clinically relevant non-major were compared across three anticoagulation strategies: 1) therapeutic, 2) prophylactic, 3) no anticoagulation.
Results
Mean age was 44; 48% were male; 50% were White; 22% were Hispanic or Latino. Overall, 24% were hospitalized, of whom 14% received therapeutic, 56% prophylactic, 21% no anticoagulation with missing data for 9%. Among non-hospitalized patients, 0.9% received therapeutic, 0.5% prophylactic, 64% no anticoagulation. Frequency of major or clinically relevant non-major bleeding increased with anticoagulation intensity among hospitalized patients (p<0.001, Table).
Conclusion
In patients with COVID-19 at University of Colorado Hospital a range of anticoagulation strategies were utilized with variation by hospitalization status and time. Major bleeding was more frequent with therapeutic anticoagulation. These observations support the need to investigate the risks and benefits of anticoagulation strategies in ongoing clinical trials.
Footnotes
Poster Contributions
Sunday, May 16, 2021, 9:45 a.m.-10:30 a.m.
Session Title: Spotlight on Special Topics: COVID 4
Abstract Category: 61. Spotlight on Special Topics: Coronavirus Disease (COVID-19)